DURECT CorpNASDAQ:DRRX
- LAST PRICE1.4000
- TODAY'S CHANGE (%)-0.1200 (-7.8947%)
- Bid / Lots1.4000/ 4
- Ask / Lots1.4200/ 23
- Open / Previous Close1.4700 / 1.5200
- Day Range
- 52 Week Range
- Volume135,551
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DRRX |
|---|---|---|
| 09:32 ET | 1223 | 1.47 |
| 09:34 ET | 734 | 1.46 |
| 09:36 ET | 1123 | 1.43 |
| 09:38 ET | 100 | 1.4399 |
| 09:39 ET | 156 | 1.4399 |
| 09:45 ET | 100 | 1.4201 |
| 09:50 ET | 100 | 1.43 |
| 09:52 ET | 100 | 1.43 |
| 09:54 ET | 2000 | 1.42 |
| 09:57 ET | 4031 | 1.42 |
| 09:59 ET | 400 | 1.43 |
| 10:01 ET | 400 | 1.428 |
| 10:03 ET | 100 | 1.422 |
| 10:06 ET | 460 | 1.4225 |
| 10:08 ET | 2500 | 1.43 |
| 10:17 ET | 3580 | 1.42 |
| 10:28 ET | 100 | 1.42 |
| 10:30 ET | 100 | 1.41 |
| 10:32 ET | 9912 | 1.4 |
| 10:33 ET | 10392 | 1.38 |
| 10:35 ET | 354 | 1.411 |
| 10:37 ET | 9928 | 1.35 |
| 10:39 ET | 2009 | 1.3505 |
| 10:44 ET | 1122 | 1.37 |
| 10:50 ET | 100 | 1.41 |
| 10:51 ET | 4000 | 1.42 |
| 10:53 ET | 3154 | 1.4 |
| 11:00 ET | 100 | 1.41 |
| 11:06 ET | 100 | 1.4 |
| 11:15 ET | 3000 | 1.4169 |
| 11:18 ET | 3316 | 1.4 |
| 11:22 ET | 3017 | 1.4 |
| 11:24 ET | 10285 | 1.41 |
| 11:36 ET | 1000 | 1.4001 |
| 11:40 ET | 100 | 1.41 |
| 11:44 ET | 20268 | 1.36 |
| 11:45 ET | 100 | 1.38 |
| 11:49 ET | 200 | 1.4 |
| 11:56 ET | 100 | 1.38 |
| 12:02 ET | 100 | 1.37 |
| 12:05 ET | 100 | 1.381 |
| 12:12 ET | 700 | 1.395 |
| 12:23 ET | 2093 | 1.3901 |
| 12:25 ET | 100 | 1.38 |
| 12:34 ET | 2500 | 1.3801 |
| 12:38 ET | 100 | 1.38 |
| 12:41 ET | 100 | 1.381 |
| 12:43 ET | 100 | 1.38 |
| 12:50 ET | 100 | 1.41 |
| 12:52 ET | 206 | 1.395 |
| 12:54 ET | 100 | 1.4 |
| 12:59 ET | 100 | 1.405 |
| 01:15 ET | 100 | 1.4 |
| 01:17 ET | 170 | 1.401 |
| 01:26 ET | 6300 | 1.405 |
| 01:30 ET | 180 | 1.4002 |
| 01:48 ET | 100 | 1.405 |
| 01:50 ET | 100 | 1.4 |
| 01:57 ET | 2046 | 1.405 |
| 02:02 ET | 200 | 1.41 |
| 02:18 ET | 100 | 1.41 |
| 02:24 ET | 200 | 1.4 |
| 02:26 ET | 600 | 1.4 |
| 02:36 ET | 150 | 1.4 |
| 02:42 ET | 100 | 1.39 |
| 02:45 ET | 200 | 1.4012 |
| 02:54 ET | 572 | 1.3904 |
| 03:02 ET | 445 | 1.4 |
| 03:09 ET | 206 | 1.39 |
| 03:12 ET | 100 | 1.39 |
| 03:18 ET | 9370 | 1.3901 |
| 03:32 ET | 500 | 1.41 |
| 03:34 ET | 100 | 1.4 |
May 21, 2024
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones
8:00AM ET on Tuesday May 21, 2024 by Dow Jones
May 13, 2024
*DJ Durect 1Q Loss/Shr 25c >DRRX, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow JonesDURECT Corporation Reports First Quarter 2024 Financial Results and Business Update, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DURECT Corp | 48.7M | -1.6x | --- |
Kezar Life Sciences Inc | 50.8M | -0.5x | --- |
Curis Inc | 56.2M | -0.9x | --- |
Kronos Bio Inc | 45.1M | -0.5x | --- |
Atara Biotherapeutics Inc | 69.7M | -0.2x | --- |
LAVA Therapeutics NV | 60.7M | -2.1x | --- |
Company Information
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
Contact Information
- Headquarters
- 10240 Bubb RoadCUPERTINO, CA, United States 95014
- Phone
- 408-777-1417
- Fax
- 408-777-3577
Executives
- Independent Chairman of the Board
- Gail Maderis
- President, Chief Executive Officer, Director
- James Brown
- Chief Financial Officer, Company Secretary
- Timothy Papp
- Senior Vice President - Operations and Corporate Quality Assurance
- Judy Joice
- Chief Medical Officer
- Norman Sussman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.7M |
|---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-0.87 |
Book Value | $0.49 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -379.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
